| Literature DB >> 12113074 |
Abstract
Ovarian cancer is a highly chemotherapy-sensitive malignancy. With current treatment, most women presenting with advanced disease will achieve an objective response and experience major and sustained improvement of cancer-related symptoms. Unfortunately, the majority of patients will ultimately recur, such that second-line treatment options will need to be considered. Further complicating the decision-making process in choosing an 'optimal' second-line regimen is a serious paucity of randomized trials in this clinical setting.Entities:
Mesh:
Year: 2002 PMID: 12113074 DOI: 10.1586/14737140.2.1.90
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN: 1473-7140 Impact factor: 4.512